Latest Breaking News On - Patrickb mark - Page 1 : comparemela.com

Empagliflozin s efficacy in a range of patients with chronic kidney disease in EMPA-Kidney filled evidence gaps and confirmed SGLT2 inhibitors as a key treatment regardless of diabetes status.

United statesUnited kingdomNatalie staplinPatrickb markJanani rangaswamiNaveed sattarAmerican heart associationBoehringer ingelheimUniversity of glasgowRenal studies group at oxford universityAmerican society of nephrologyGeorge washington university school of medicineNovo nordiskHealth sciencesNew england journalKidney week